|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Tumor sensitivity to MMC, as indicated by the inverse of IC(50) values, was positively correlated with the expression of DTD (r(2), 0.28; P < 0.05) and P450R (r(2), 0.26; P < 0.05).
|
11350900 |
2001 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tumour tissue was analysed for NQO1 expression.
|
30318513 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 is known to catalyse metabolic detoxification of quinones and protect cells from redox cycling, oxidative stress and neoplasia.
|
11154737 |
2000 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1 gene expression was higher in the tumor than in the matched normal lung tissue in 27/50 (59%) patients (p=0.014).
|
12370763 |
2002 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 deficiency promotes estrogen-dependent tumor formation, and shikonin inhibits estrogen-dependent tumor growth in an NQO1-dependent manner in MCF-7 xenografts.
|
20623181 |
2010 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1 protein expression was associated with estrogen receptor (ER) expression (P = 0.011), whereas 34.5% of NFκB-nuclear/activated tumors were ER negative (P = 0.001).
|
21706157 |
2012 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1 protein expression was assessed using immunohistochemical (IHC) staining in 160 patients with serous ovarian carcinoma, 62 patients with ovarian borderline tumors and 53 patients with benign ovarian tumors.
|
25885439 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 genotypes of 390 men did not indicate predisposition to CaP, yet loss of NQO1 in CaP suggested potential progression-opposing tumour suppressor role.
|
26987799 |
2016 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 and HO-1 positive tumors showed nearly complete expression of Nrf2 in the nucleus and/or showed partial expression in the nucleus/cytoplasm (nNrf2); however, tumors negative for NQO1 and HO-1 showed almost complete expression of Nrf2 in the cytoplasm and/or partial expression in the nucleus/cytoplasm (cNrf2).
|
27033953 |
2016 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1: catalase levels (high in tumor, low in normal tissue) are an attractive therapeutic window to treat pancreatic cancer.
|
28346693 |
2017 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1 overexpression correlated to tumor size, venous infiltration and late pTNM stage of HCC.
|
28964792 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H quinone oxidoreductase 1 (NQO1)-dependent antitumor drugs such as β-lapachone (β-lap) are attractive candidates for cancer chemotherapy because several tumors exhibit higher expression of NQO1 than adjacent tissues.
|
29434949 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A broad spectrum of NQO1 protein expression existed in tumours genotyped as NQO1*1 and NQO1*1/*2 although tumours with NQO1*1 typically expressed higher NQO1 protein.
|
15375541 |
2004 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A novel anticancer agent RH1 is designed as pro-drug to be activated by NQO1, an enzyme overexpressed in many types of tumors.
|
28879492 |
2017 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Additionally, the NQO1 expression rate was positively correlated with tumor size, serosal invasion, tumor stage, and both disease-free survival and 5-year survival rates.
|
24384455 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed.
|
22532167 |
2012 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Analysis of RNA indicated 20- to 50-fold higher levels of NQO1 gene expression in the liver tumors and in the tissue surrounding the tumors of patients with hepatocarcinoma than in normal individuals.
|
1651729 |
1991 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Correction to: JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
|
29880796 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Correction to: JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
|
29880865 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Developing an effective method for detecting NQO1 activity with high sensitivity and selectivity in tumors holds a great potential for cancer diagnosis, treatment, and management.
|
30487423 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Following activation by NQO1, IB-DNQ participates in a catalytic futile reduction/reoxidation cycle with consequent toxic reactive oxygen species generation within the tumor microenvironment.
|
27975234 |
2017 |
|
Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Furthermore, NQO1 protects tumour suppressors like p53, p33<sup>ING</sup><sup>1b</sup> and p73 from proteasomal degradation.
|
28236663 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, the effect of NQO1 and SIRT6 on tumor growth was determined in cell model and orthotopic tumor implantation model.
|
31842909 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, the intracellular delivery of RNase A-QPN using a novel type of lipid-based nanoparticles, and subsequent protein activation by cellular NQO1, selectively inhibit cancer cell growth in vitro and effectively suppress tumor growth in vivo.
|
31589435 |
2019 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genetically determined variations in NQO1 may modify the risk for CRC and these risks may be greatest for tumors containing K-ras codon 12 mutations.
|
11023538 |
2000 |